| From bench to bedside--translational research in psoriasis. | |
| | |
MedLine Citation:
|
PMID: 20831702 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
For many years, psoriasis was firmly believed to be a disease of epidermal keratinocytes, but now is attributed to a combination of genetic and environmental factors that promote a T-cell mediated immune response in the skin. Psoriasis is now understood to be a systemic T-cell mediated autoimmune disease with the innate immune system playing an important role. Progress in understanding the pathogenesis of psoriasis has shown that following a stimulus, dendritic and T cell activation leads to the release of cytokines, chemokines and growth factors that initiate the proliferation and altered differentiation of keratinocytes. These factors subsequently lead to continuous activation of T cells and antigen-presenting cells, particularly dendritic cells, within the psoriatic plaque. This vicious cycle of psoriasis, in which the cytokines interleukin 12 (IL-12) and IL-23 play a pivotal role, is a logical target for biological therapy. |
| | |
Authors:
|
J C Prinz |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of the European Academy of Dermatology and Venereology : JEADV Volume: 24 Suppl 6 ISSN: 1468-3083 ISO Abbreviation: J Eur Acad Dermatol Venereol Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-13 Completed Date: 2010-12-13 Revised Date: 2011-07-29 |
Medline Journal Info:
|
Nlm Unique ID: 9216037 Medline TA: J Eur Acad Dermatol Venereol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1-4 Citation Subset: IM |
Copyright Information:
|
© 2010 The Author. JEADV © 2010 European Academy of Dermatology and Venereology. |
Affiliation:
|
Department of Dermatology, University of Munich, Munich, Germany. joerg.prinz@med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects,
therapeutic use* Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Humans Immunologic Factors / adverse effects, therapeutic use* Interleukin-12 / immunology Interleukin-23 / immunology Lymphocyte Activation Psoriasis / immunology, therapy* Randomized Controlled Trials as Topic Severity of Illness Index T-Lymphocytes / immunology Translational Research* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/ABT-874 antibody, human; 0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Interleukin-23; 0/ustekinumab; 187348-17-0/Interleukin-12 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cutaneous epidermal growth factor receptor system following ultraviolet irradiation: exploring the r...
Next Document: Novel biologic therapies in development targeting IL-12/IL-23.